Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : the TROPIC study in France
In 2010, results of the TROPIC study demonstrated that, when compared to mitxantrone, the novel taxane cabazitaxel improved median overall survival of patients with metastatic castration-resistant prostate cancer who progressed on or after docetaxel treatment. We report the data on efficacy and toxicity observed in the subgroup of patients included in the French centers. In this phase III randomized international trial, patients received prednisone and were treated with either 25 mg/m(2) cabazitaxel or 12 mg/m(2) mitoxantrone intravenously every three weeks. The primary endpoint was overall survival. The secondary endpoints included progression-free survival (PFS) and safety. Analyses were performed on the intention-to-treat population. Among the 90 patients enrolled in France, the median overall survival was 18 months for the cabazitaxel arm versus 14.3 months for the mitoxantrone arm. An improvement in PFS was also observed, with a median of 1.4 months for the mitoxatrone arm compared to a median of 2.5 months for the cabazitaxel arm. The most common grade ≥ 3 adverse events were hematologic with neutropenia, usually afebrile and digestive with 4 % of patients reporting diarrhea. These results are comparable to those reported for the overall population and the safety profile remains favorable without any toxic death related to cabazitaxel.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Bulletin du cancer - 99(2012), 7-8 vom: 15. Juli, Seite 731-41 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Cabazitaxel dans le cancer de la prostate métastatique résistant à la castration ayant progressé pendant ou après traitement par docétaxel : l'expérience française de l'essai TROPIC |
|---|
| Beteiligte Personen: |
Pouessel, Damien [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.09.2012 Date Revised 01.12.2018 published: Print ClinicalTrials.gov: NCT00417079 Citation Status MEDLINE |
|---|
| doi: |
10.1684/bdc.2012.1608 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM219016615 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM219016615 | ||
| 003 | DE-627 | ||
| 005 | 20231224041905.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1684/bdc.2012.1608 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0730.xml |
| 035 | |a (DE-627)NLM219016615 | ||
| 035 | |a (NLM)22743148 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Pouessel, Damien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment |b the TROPIC study in France |
| 246 | 3 | 3 | |a Cabazitaxel dans le cancer de la prostate métastatique résistant à la castration ayant progressé pendant ou après traitement par docétaxel : l'expérience française de l'essai TROPIC |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2012 | ||
| 500 | |a Date Revised 01.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT00417079 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In 2010, results of the TROPIC study demonstrated that, when compared to mitxantrone, the novel taxane cabazitaxel improved median overall survival of patients with metastatic castration-resistant prostate cancer who progressed on or after docetaxel treatment. We report the data on efficacy and toxicity observed in the subgroup of patients included in the French centers. In this phase III randomized international trial, patients received prednisone and were treated with either 25 mg/m(2) cabazitaxel or 12 mg/m(2) mitoxantrone intravenously every three weeks. The primary endpoint was overall survival. The secondary endpoints included progression-free survival (PFS) and safety. Analyses were performed on the intention-to-treat population. Among the 90 patients enrolled in France, the median overall survival was 18 months for the cabazitaxel arm versus 14.3 months for the mitoxantrone arm. An improvement in PFS was also observed, with a median of 1.4 months for the mitoxatrone arm compared to a median of 2.5 months for the cabazitaxel arm. The most common grade ≥ 3 adverse events were hematologic with neutropenia, usually afebrile and digestive with 4 % of patients reporting diarrhea. These results are comparable to those reported for the overall population and the safety profile remains favorable without any toxic death related to cabazitaxel | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Androgen Antagonists |2 NLM | |
| 650 | 7 | |a Taxoids |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a cabazitaxel |2 NLM | |
| 650 | 7 | |a 51F690397J |2 NLM | |
| 650 | 7 | |a Mitoxantrone |2 NLM | |
| 650 | 7 | |a BZ114NVM5P |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Oudard, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Gravis, Gwenaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Priou, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Liji |e verfasserin |4 aut | |
| 700 | 1 | |a Culine, Stéphane |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin du cancer |d 1966 |g 99(2012), 7-8 vom: 15. Juli, Seite 731-41 |w (DE-627)NLM000155853 |x 1769-6917 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2012 |g number:7-8 |g day:15 |g month:07 |g pages:731-41 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/bdc.2012.1608 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2012 |e 7-8 |b 15 |c 07 |h 731-41 | ||